Recent meaningful negative changes in fundamentals have impacted Theravance Biopharma Inc (NASDAQ: TBPH): the stock’s power rating fell below 50, the consensus estimate for December, 2025 decreased significantly, and the consensus estimate for December, 2026 decreased significantly.
Recent meaningful negative changes in investment behavior have impacted Theravance Biopharma Inc (NASDAQ: TBPH): the stock’s recent price decline challenged its longer term uptrend.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Theravance Biopharma has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Theravance Biopharma has a neutral Power Rating of 48 but a very low Appreciation Score of 12, triggering the Lowest Value Trend Rating.
Recent Price Action
On 3/31/25, Theravance Biopharma Inc (NASDAQ: TBPH) stock declined by -3.3%, closing at $8.93. Moreover, unusually high trading volume at 155% of normal accompanied the decline. The stock has declined -4.9% during the last week but has been strong relative to the market over the last nine months.
Be the first to comment